Moderna Inc (MRNA)
Debt-to-capital ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 13,854,000 | 19,123,000 | 14,145,000 | 2,561,000 | 1,175,000 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $13,854,000K)
= 0.00
Moderna Inc's debt-to-capital ratio has remained relatively stable over the past five years. The company's debt-to-capital ratio was 0.04 at the end of 2023, down slightly from 0.05 in 2022, 2021, and 2020, but higher than the ratio of 0.03 in 2019. This indicates that Moderna Inc has a relatively low level of debt compared to its total capital structure.
A low debt-to-capital ratio generally suggests that the company relies less on debt financing and has a stronger equity base to support its operations. Moderna Inc's consistent low debt-to-capital ratio over the years indicates a conservative approach to debt management, which can be seen as a positive indicator of financial stability and lower financial risk.
However, it is essential to consider the industry norms and trends in the economic environment when evaluating the debt-to-capital ratio. Overall, based on the historical data provided, Moderna Inc's debt-to-capital ratio demonstrates a prudent debt management strategy and financial strength.
Peer comparison
Dec 31, 2023